The invention relates to an electronic device comprising a compound having Formula (1): AB.sub.x (1), wherein A is a structural moiety that consists of at least two atoms and comprises a conjugated system of delocalized electrons, each B is independently selected from an imine functional group (1a), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 are independently selected from C.sub.1-C.sub.30 alkyl, C.sub.2-C.sub.30 alkenyl, C.sub.2-C.sub.3 alkinyl, C.sub.3-C.sub.30 cycloalkyl, C.sub.6-C.sub.30 aryl, C.sub.2-C.sub.30 heteroaryl, C.sub.7-C.sub.30 arylalkyl, C.sub.3-C.sub.30 heteroarylalkyl, the wave line represents a covalent bond to the imine nitrogen atom, G is in each group (1a) independently selected from a quarternary carbon atom and from a cyclopropenylidene structural moiety, x is an integer equal one or higher, preferably equal two or higher, and the lone electron pair of the imine nitrogen atom and/or the pi-electrons of the imine double bond of at least one group B is conjugated with the conjugated system of delocalized electrons comprised in the structural moiety A, with the proviso that two or more of the substituents R.sup.1, R.sup.2, R.sup.3, R.sup.4 may be connected to form a ring that may contain also unsaturation and, if any of the substituents R.sup.1, R.sup.2, R.sup.3, R.sup.4 comprises two or more carbon atoms, up to one third of the overall count of the carbon atoms in the substituent or in any ring formed by two connected substituents can be replaced with heteroatoms independently selected from O, S, N and B as well as to an electrically semiconducting material and a compound for use in the electronic device. ##STR00001##

The invention relates to an electronic device comprising a compound having Formula (1): AB.sub.x (1), wherein A is a structural moiety that consists of at least two atoms and comprises a conjugated system of delocalized electrons, each B is independently selected from an imine functional group (1a), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 are independently selected from C.sub.1-C.sub.30 alkyl, C.sub.2-C.sub.30 alkenyl, C.sub.2-C.sub.3 alkinyl, C.sub.3-C.sub.30 cycloalkyl, C.sub.6-C.sub.30 aryl, C.sub.2-C.sub.30 heteroaryl, C.sub.7-C.sub.30 arylalkyl, C.sub.3-C.sub.30 heteroarylalkyl, the wave line represents a covalent bond to the imine nitrogen atom, G is in each group (1a) independently selected from a quarternary carbon atom and from a cyclopropenylidene structural moiety, x is an integer equal one or higher, preferably equal two or higher, and the lone electron pair of the imine nitrogen atom and/or the pi-electrons of the imine double bond of at least one group B is conjugated with the conjugated system of delocalized electrons comprised in the structural moiety A, with the proviso that two or more of the substituents R.sup.1, R.sup.2, R.sup.3, R.sup.4 may be connected to form a ring that may contain also unsaturation and, if any of the substituents R.sup.1, R.sup.2, R.sup.3, R.sup.4 comprises two or more carbon atoms, up to one third of the overall count of the carbon atoms in the substituent or in any ring formed by two connected substituents can be replaced with heteroatoms independently selected from O, S, N and B as well as to an electrically semiconducting material and a compound for use in the electronic device. ##STR00001##

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: ##STR00001## wherein X is a divalent linking moiety; and R.sup.1-R.sup.10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R.sup.3 or R.sup.8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: ##STR00001## wherein X is a divalent linking moiety; and R.sup.1-R.sup.10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R.sup.3 or R.sup.8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: ##STR00001## wherein X is a divalent linking moiety; and R.sup.1-R.sup.10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R.sup.3 or R.sup.8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: ##STR00001## wherein X is a divalent linking moiety; and R.sup.1-R.sup.10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R.sup.3 or R.sup.8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:

##STR00001## wherein X is a divalent linking moiety; and R.sup.1-R.sup.10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R.sup.3 or R.sup.8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:

##STR00001## wherein X is a divalent linking moiety; and R.sup.1-R.sup.10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R.sup.3 or R.sup.8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.